Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000611013 | Oral cavity | NEOLP | regulation of glycolytic process | 11/2005 | 45/18723 | 6.72e-03 | 3.42e-02 | 11 |
GO:000915025 | Oral cavity | NEOLP | purine ribonucleotide metabolic process | 55/2005 | 368/18723 | 6.80e-03 | 3.46e-02 | 55 |
GO:009893021 | Oral cavity | NEOLP | axonal transport | 14/2005 | 64/18723 | 6.92e-03 | 3.51e-02 | 14 |
GO:000925925 | Oral cavity | NEOLP | ribonucleotide metabolic process | 57/2005 | 385/18723 | 7.23e-03 | 3.66e-02 | 57 |
GO:000609024 | Oral cavity | NEOLP | pyruvate metabolic process | 20/2005 | 106/18723 | 8.31e-03 | 4.08e-02 | 20 |
GO:003516211 | Oral cavity | NEOLP | embryonic hemopoiesis | 7/2005 | 23/18723 | 8.34e-03 | 4.08e-02 | 7 |
GO:001969325 | Oral cavity | NEOLP | ribose phosphate metabolic process | 58/2005 | 396/18723 | 8.46e-03 | 4.13e-02 | 58 |
GO:00614182 | Oral cavity | NEOLP | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 5/2005 | 13/18723 | 8.62e-03 | 4.15e-02 | 5 |
GO:006056215 | Oral cavity | NEOLP | epithelial tube morphogenesis | 49/2005 | 325/18723 | 8.68e-03 | 4.17e-02 | 49 |
GO:002198721 | Oral cavity | NEOLP | cerebral cortex development | 21/2005 | 114/18723 | 9.16e-03 | 4.37e-02 | 21 |
GO:00485921 | Oral cavity | NEOLP | eye morphogenesis | 26/2005 | 151/18723 | 9.93e-03 | 4.65e-02 | 26 |
GO:004259324 | Oral cavity | NEOLP | glucose homeostasis | 40/2005 | 258/18723 | 1.06e-02 | 4.93e-02 | 40 |
GO:004603418 | Prostate | BPH | ATP metabolic process | 120/3107 | 277/18723 | 4.78e-26 | 1.48e-22 | 120 |
GO:200123318 | Prostate | BPH | regulation of apoptotic signaling pathway | 134/3107 | 356/18723 | 5.06e-22 | 7.84e-19 | 134 |
GO:000906016 | Prostate | BPH | aerobic respiration | 86/3107 | 189/18723 | 9.81e-21 | 1.01e-17 | 86 |
GO:000609116 | Prostate | BPH | generation of precursor metabolites and energy | 161/3107 | 490/18723 | 3.05e-19 | 1.45e-16 | 161 |
GO:009719318 | Prostate | BPH | intrinsic apoptotic signaling pathway | 110/3107 | 288/18723 | 7.36e-19 | 2.85e-16 | 110 |
GO:001598016 | Prostate | BPH | energy derivation by oxidation of organic compounds | 115/3107 | 318/18723 | 1.55e-17 | 4.36e-15 | 115 |
GO:004533316 | Prostate | BPH | cellular respiration | 92/3107 | 230/18723 | 1.67e-17 | 4.49e-15 | 92 |
GO:000989618 | Prostate | BPH | positive regulation of catabolic process | 156/3107 | 492/18723 | 4.50e-17 | 1.11e-14 | 156 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0413718 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
hsa046596 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa052119 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406618 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0413719 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
hsa0465911 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa0521114 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa0406619 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
HIF1A | MLUM | Breast | Healthy | TGM2,BZW1,NAMPT, etc. | 4.62e-01 | |
HIF1A | MES | Cervix | CC | HIF1A-AS3,SNAPC1,KRT6C, etc. | 7.02e-01 | |
HIF1A | PERI | Colorectum | FAP | SSH1,NUAK1,RUNX1, etc. | 4.34e-02 | |
HIF1A | ICAF | Colorectum | SER | SSH1,NUAK1,RUNX1, etc. | 3.93e-01 | |
HIF1A | PMC | Stomach | CAG with IM | PLPP3,SERPINA3,SOD2, etc. | 2.12e-01 | |
HIF1A | GMC | Stomach | CAG with IM | PLPP3,SERPINA3,SOD2, etc. | 1.31e-01 | |
HIF1A | PMC | Stomach | SIM | PLPP3,SERPINA3,SOD2, etc. | 4.96e-01 | |
HIF1A | GMC | Stomach | WIM | PLPP3,SERPINA3,SOD2, etc. | 7.45e-02 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HIF1A | SNV | Missense_Mutation | novel | c.1022T>G | p.Val341Gly | p.V341G | Q16665 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
HIF1A | SNV | Missense_Mutation | rs540883086 | c.853N>A | p.Glu285Lys | p.E285K | Q16665 | protein_coding | deleterious(0) | possibly_damaging(0.473) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | | c.1713N>T | p.Lys571Asn | p.K571N | Q16665 | protein_coding | tolerated(0.1) | probably_damaging(0.916) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | novel | c.1752N>T | p.Glu584Asp | p.E584D | Q16665 | protein_coding | deleterious(0.01) | possibly_damaging(0.557) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | rs746540920 | c.157N>T | p.Arg53Trp | p.R53W | Q16665 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | | c.2485N>G | p.Pro829Ala | p.P829A | Q16665 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
HIF1A | SNV | Missense_Mutation | | c.1996C>T | p.Pro666Ser | p.P666S | Q16665 | protein_coding | tolerated(0.1) | benign(0.01) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
HIF1A | SNV | Missense_Mutation | rs776377120 | c.196C>T | p.His66Tyr | p.H66Y | Q16665 | protein_coding | deleterious(0.02) | benign(0.023) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
HIF1A | SNV | Missense_Mutation | novel | c.2122C>G | p.His708Asp | p.H708D | Q16665 | protein_coding | tolerated(0.2) | benign(0.07) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HIF1A | SNV | Missense_Mutation | | c.412G>C | p.Asp138His | p.D138H | Q16665 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | SP-600125 | SP-600125 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | LEVONORDEFRIN | LEVONORDEFRIN | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | DNDI1417388 | CHEMBL1528359 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | NOSCAPINE | NOSCAPINE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | NSC-117079 | CHEMBL471225 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | TYRPHOSTIN A9 | TYRPHOSTIN A9 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | PX-478 | PX-478 | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | PIMOZIDE | PIMOZIDE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | BECLOMETHASONE | BECLOMETHASONE | |
3091 | HIF1A | TRANSPORTER, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE | | GELDANAMYCIN | GELDANAMYCIN | 12811834 |